Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial
Posted inCardiology news

Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial

The APERITIF trial explored adding low-dose rivaroxaban to standard dual antiplatelet therapy to prevent heart clots after an anterior heart attack. While the addition did not significantly reduce thrombus formation, it did increase minor bleeding risk, suggesting a need for cautious clinical application.
Taurochenodeoxycholic Acid: A Novel Metabolic Sentinel Reversing Obesity-Induced Endothelial Dysfunction via the FXR-PHB1-ATF4 Axis
Posted inCardiology Diabetes & Endocrinology news

Taurochenodeoxycholic Acid: A Novel Metabolic Sentinel Reversing Obesity-Induced Endothelial Dysfunction via the FXR-PHB1-ATF4 Axis

This study identifies TCDCA as a key metabolite that restores endothelial function in obesity. By activating the endothelial FXR-PHB1-ATF4 pathway, TCDCA enhances serine metabolism, offering a promising therapeutic strategy to mitigate cardiovascular risk in obese populations.
Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis
Posted inCardiology Internal Medicine news

Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis

This large retrospective study of 820 patients reveals that restrictive ventricular physiology is the most common phenotype in cardiac amyloidosis. While preserved LV function offers better initial survival, the rate of progression to restriction is high, emphasizing the need for early clinical detection.